3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumors
11
Mesothelioma, Malignant
8
Solid Tumor
6
Advanced Solid Tumor
6
Mesothelioma
3
Melanoma
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Advanced Solid Tumors
3
Treatment-Refractory Solid Tumors
2
Squamous Cell Carcinoma of Head and Neck
2
Carcinoma, Merkel Cell
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Solid Tumour
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Select Advanced Solid Tumors
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Locally Advanced or Metastatic Solid Tumors
1
Locally Advanced Solid Tumors
1
Locally Advanced Solid Tumor
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Gastrointestinal Neoplasms
1
Interventions
pembrolizumab
7
Radiotherapy
3
Proton Therapy
3
Interleukin-2
3
Cyclophosphamide
3
spartalizumab
2
fludarabine
2
Rosuvastatin Calcium
2
Paclitaxel
2
Ipilimumab
2
Immune Checkpoint Inhibitors
2
Cetuximab
2
Carboplatin
2
Blood Specimen Collection
2
toripalimab
1
tislelizumab
1
sotorasib
1
peposertib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
niraparib
1
neotil
1
necitumumab
1
mirdametinib
1
leronlimab
1
lenvatinib
1
atezolizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor, Adult
×
atezolizumab
×
Other solid neoplasm
×
Clear all
NCT06003621
2024-11-15
MoST-TAP
Omico
Phase 2
Recruiting
96 enrolled